Evidence map›Paper›PMID 29394905›Full record

ArticleTrials2018

National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme research funding and UK burden of disease.

Fay Chinnery, Gemma Bashevoy, Amanda Blatch-Jones, Lisa Douet, Sarah Puddicombe, James Raftery

Abstract readComparative Study
In one paragraph

Article in Trials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fay ChinneryWessex Institute, University of Southampton, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS, UK. F.Chinnery@soton.ac.uk.ORCID http://orcid.org/0000-0002-8082-9016
Gemma BashevoyNational Institute for Health Research (NIHR), Evaluation, Trials and Studies Coordinating Centre (NETSCC), University of Southampton, Southampton, SO16 7NS, UK.
Amanda Blatch-JonesWessex Institute, University of Southampton, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS, UK.
Lisa DouetNational Institute for Health Research (NIHR), Evaluation, Trials and Studies Coordinating Centre (NETSCC), University of Southampton, Southampton, SO16 7NS, UK.
Sarah PuddicombeNational Institute for Health Research (NIHR), Evaluation, Trials and Studies Coordinating Centre (NETSCC), University of Southampton, Southampton, SO16 7NS, UK.
James RafteryWessex Institute, University of Southampton, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHTA Programme funding is governed by the need for evidence and scientific quality, reflecting funding of the National Institute for Health Research (NIHR) by the NHS. The need criterion incorporates covering the spectrum of diseases, but also taking account of research supported by other funders. This study compared the NIHR HTA Programme portfolio of research with the UK burden of disease as measured by Disability-adjusted Life Years (DALYs).

methodsA retrospective cross-sectional study using a cohort of all funded primary research and evidence syntheses projects received by the HTA Programme from April 2011 to March 2016 (n = 363); to determine the proportion of spend by disease compared with burden of disease in the UK calculated using 2015 UK DALY data.

resultsThe programme costing just under £44 million broadly reflected UK DALY burden by disease. Spend was lower than disease burden for cancer, cardiovascular and musculoskeletal diseases, which may reflect the importance of other funders, notably medical charities, which concentrate on these diseases.

conclusionThe HTA Programme spend, adjusted for other relevant funders, broadly matches disease burden in the UK; no diseases are being neglected.

Indexed as

Disability EvaluationQuality-Adjusted Life YearsAcademies and InstitutesBiomedical ResearchCost of IllnessCross-Sectional StudiesHealth Services Needs and DemandHumansNeeds AssessmentProgram EvaluationResearch Support as TopicRetrospective StudiesTechnology Assessment, BiomedicalTime FactorsUnited KingdomBurden of diseaseDisability-adjusted life yearsFundingHealth Technology Assessment ProgrammeNational Institute for Health Research

Identifiers

PMID29394905
PMCPMC5797405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.